Martha Morin, RPH in Akron, IA - Pharmacist

Martha Morin, RPH is a Pharmacist based in Akron, Iowa. Martha Morin is licensed to practice in Iowa (license number 457) and her current practice location is 233 Reed St, Akron, Iowa. She can be reached at her office (for appointments etc.) via phone at (712) 568-2013.

NPI number for Martha Morin is 1942237185 and her current mailing address is Po Box 800, Akron, Iowa. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1942237185.

Contact Information

	Martha Morin, RPH
	233 Reed St, Akron, IA 51001
	(712) 568-2013
	(712) 568-2711

Healthcare Provider's Profile

Full Name	Martha Morin
Gender	Female
Speciality	Pharmacist
Location	233 Reed St, Akron, Iowa
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1942237185
Provider Enumeration Date: 06/26/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Martha Morin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1942237185	NPI	-	NPPES
0036731	Medicaid	IA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	457 (Iowa)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Martha Morin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Martha Morin, RPH Po Box 800, Akron, IA 51001-0800 Ph: () -	Martha Morin, RPH 233 Reed St, Akron, IA 51001 Ph: (712) 568-2013

News Archive

Identification of Gli protein degradation signals that directly affect tumor latency

Dr. Anthony E. Oro and colleagues (Stanford University) have identified two key Gli protein degradation signals that directly affect tumor latency in a mouse model of human skin cancer.

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

Michigan Bills introduced that would require girls to receive HPV vaccine before sixth grade

Michigan Sen. Beverly Hammerstrom (R) last Tuesday introduced two bills (SB 1416, SB 1417) that would require girls in the state entering the sixth grade in the 2007-2008 school year and beyond to have received Merck's human papillomavirus vaccine Gardasil, the Detroit News reports.

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.

Pharmacist in Akron, IA

Taylor Pies,
Pharmacist
Medicare: Not Enrolled in Medicare
Practice Location: 233 Reed St, Akron, IA 51001
Phone: 712-568-2013 Fax: 712-568-2711

Martha Morin, RPH - Pharmacist in Akron, IA